Skip to main content
. 2020 Aug 21;10:1216. doi: 10.3389/fonc.2020.01216

Figure 3.

Figure 3

(A) Progression-free survival (PFS) according to concomitant mutations. (B) Hazard ratios (HR) were evaluated by Cox regression. CI, confidence interval; ECOG, Eastern Cooperative Oncology Group performance status.